Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing

Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing

The anticancer efficacy of Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate internalized through a sortilin-mediated process, was assessed in a triple-negative breast cancer-derived MDA-MB-231 immunocompromised xenograft tumor model where complete tumor regression was observed for more th...

Full description

Bibliographic Details
Main Authors: Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Véronique Lullier, Richard Béliveau, Christian Marsolais, Borhane Annabi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Immunology
Subjects:
peptide-drug conjugate
checkpoint inhibitor
docetaxel
sortilin
STING
immune tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1355945/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1355945/full

Similar Items